MiMedx outlines $250M-$260M 2026 net sales as it targets >20% adjusted EBITDA margin with Sanara

• “The results and trends of the third quarter reinforce the strategic rationale for the direction we are taking the company.” (CEO & Director Joseph Capper)
• “However, as previously announced, the FTC has issued a second request for information, which extends the Hart-Scott-Rodino waiting period.” (CEO & Director Capper)
• “For the third quarter, net sales were $62 million.” (CEO & Director Capper) “GAAP gross profit was 80% in the quarter, a sequential improvement of 11 percentage points.” (CEO & Director Capper) “Adjusted EBITDA was $2 million, a $10 million sequential improvement.” (CEO & Director Capper)
• “As announced today, we reached a $25 million settlement and licensing agreement with one of several parties that we believe infringed on our patent portfolio.” (CEO & Director Capper) “We continue to litigate 2 other potentially larger cases.” (CEO & Director Capper)
• “We received a significant ruling in our favor from a U.S. District Court in our challenge to the FDA's regulatory classification of AXIOFILL.” (CEO & Director Capper) “The court vacated the FDA's determination that AXIOFILL is not a Section 361 product and should instead be classified as a biologic product rather than a medical device.” (CEO & Director Capper)
• “Third quarter 2026 net sales were $62 million, down 45% from the prior year period.” (Chief Financial Officer Douglas Rice) “Surgical net sales of $40 million grew 9% year-over-year and 2% sequentially during the third quarter.” (CFO Rice) “Wound net sales were $22 million, down 71% from the prior year period.” (CFO Rice)

Outlook

• “Turning to guidance. We are updating our stand-alone 2026 outlook and now expect full year net sales of $250 million to $260 million.” (CFO Rice)
• “To finish the year, we expect high single-digit year-over-year growth in Surgical and mid-single-digit sequential growth in Wound.” (CFO Rice)
• “We expect fourth quarter gross margin to approximate the Q3 level as we continue to benefit from our cost reduction initiatives and improved throughput.” (CFO Rice)
• “For the fourth quarter, we expect sales and marketing expense of 58% to 60% of net sales.” (CFO Rice)

Financial results

• “Gross profit was $50 million compared to $95 million in the prior year period, and gross margin was 80% compared to 84%.” (CFO Rice)
• “GAAP net loss was $9 million or $0.06 per share compared to GAAP income of $17 million or $0.11 per share in the prior year period.” (CFO Rice) “Adjusted net loss for the third quarter was $1 million or $0.01 per share.” (CFO Rice)
• “We ended the quarter with $121 million in net cash.” (CFO Rice) “During the quarter, we repaid the remaining $17 million principal balance under our Citizens Term Loan.” (CFO Rice) “We ended the quarter with no borrowings outstanding under our term loan or revolving credit facilities.” (CFO Rice)
• “In light of the recent FTC news and the corresponding delay in closing the acquisition, we have started to incur a modest ticking fee associated with Hayfin's commitment.” (CFO Rice)

Q&A

• Frank Takkinen, Lake Street Capital Markets: “Maybe talk a little bit on what led to offering the rebates? And then how should we think about kind of rebate activity on a go-forward basis?” CEO & Director Capper: “It was some activity in the third quarter that was related to kind of new promotional work that we're doing short term through year-end.”
• Frank Takkinen, Lake Street Capital Markets: “Any thoughts on maybe an update related to the time line on when Sanara could close and any additional thoughts you might be comfortable sharing with the process with the FTC?” CEO & Director Capper: “I certainly don't want to put a time line on it because it's outside of my control.”
• Frank Takkinen, Lake Street Capital Markets: “Is it fair to think that, that profile can kind of stay durable on the go-forward basis into 2027 and beyond?” CFO Rice: “Going forward, I think a lot of it is going to depend on product mix, but we certainly like where we think we're going to exit the year.”
• Chase Knickerbocker, Craig-Hallum: “Do you feel like you have any better visibility to where this business stabilizes now versus last time we got an update in August?” CEO & Director Capper: “This is probably the toughest one to predict, Chase.”
• Chase Knickerbocker, Craig-Hallum: “Are there any additional one-timers that we should be thinking about for that business in Q4?” CEO & Director Capper: “I don't think you're going to see as much noise in Q4.”
• Brad Bowers, Mizuho: “Wanted to see if you still think you need the clinical studies.” CEO & Director Capper: “We are still investing in clinical studies, and we think they're really important.”
• Brad Bowers, Mizuho: “Is there any inflection point that is on your calendar?” CEO & Director Capper: “I think Smart Money is probably what we see in '26 is probably what we're going to see in '27.”

Sentiment analysis

• Analysts’ tone was neutral to slightly negative on deal timing and Wound visibility, with pointed framing such as “I know it's a sensitive topic” (Frank Takkinen, Lake Street Capital Markets) and requests for stabilization timing, “when would be helpful” (Chase Knickerbocker, Craig-Hallum).
• Management’s prepared-remarks tone was slightly positive on Surgical and portfolio reshaping, while acknowledging uncertainty in Wound and FTC timing: “we remain fully committed to the acquisition” (CEO & Director Capper) and “This is probably the toughest one to predict” (CEO & Director Capper).
• Versus the prior quarter’s more promotional M&A tone (“We are extremely excited to share the news” (CEO & Director Capper, Q2)), the current call added more constraint language around timing: “I certainly don't want to put a time line on it because it's outside of my control.” (CEO & Director Capper, Q3).

Quarter-over-quarter comparison

• Acquisition process messaging shifted from “We expect the transaction to close by year-end.” (CEO & Director Capper, Q2) to “the FTC has issued a second request for information” (CEO & Director Capper, Q3), with management declining to provide a closing timeline in Q3.
• Stand-alone 2026 outlook changed from “full-year net sales of between $260 million and $290 million” (CFO Rice, Q2) to “full year net sales of $250 million to $260 million” (CFO Rice, Q3).
• Wound narrative moved from sequential recovery emphasis (“our wound care volume increased 22% compared to Q1” (CEO & Director Capper, Q2)) to continued disruption language in Q3 (“continued disruption, pricing pressure, lower overall market volume” (CEO & Director Capper)).

Risks and concerns

• “The Wound Care market continues to work through a range of issues resulting from the 2026 Medicare reimbursement changes.” (CEO & Director Capper)
• “The market is still settling from the CMS reset that we got this year.” (CFO Rice)
• “The FTC has issued a second request for information, which extends the Hart-Scott-Rodino waiting period.” (CEO & Director Capper)

Final takeaway

Management framed Q3 around a Surgical-led mix shift and cost actions that “achieved” a return to positive adjusted EBITDA, while Wound Care remained in a reimbursement-driven reset with limited near-term catalysts beyond the final Medicare fee schedule. The call’s most market-moving updates were the FTC second request affecting Sanara closing timing, a $25 million IP settlement with two additional cases ongoing, the AXIOFILL court ruling remanding the matter to FDA, and revised stand-alone 2026 net sales guidance to $250 million to $260 million.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.